Form 4: Ligand Pharmaceuticals CFO Exercises Stock Options
SEC Form 4 Filing
Octavio Espinoza, CFO of Ligand Pharmaceuticals, exercised stock options at prices of $57.22 and $80.72 on September 17, 2024.
Summary
- On September 17, 2024, Octavio Espinoza, the Chief Financial Officer of Ligand Pharmaceuticals, exercised stock options.
- He exercised 1,417 options at a price of $80.72 per share and 69 options at a price of $57.22 per share.
- Following these transactions, Espinoza directly owns 25,885 shares of Ligand Pharmaceuticals common stock.
- He also holds derivative securities, including 7,240 employee stock options exercisable at $57.22 and 466 options exercisable at $80.72.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, so the sentiment is neither positive nor negative.
Industry Context
This filing is a routine disclosure of insider transactions and doesn't necessarily indicate a broader trend in the pharmaceutical industry. It reflects the executive's compensation and investment decisions.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it involves the exercise of existing stock options, potentially diluting shares slightly.
Key Dates
| Date | Description |
|---|---|
| 09/17/2024 | Date of stock option exercise. |
| 09/19/2024 | Date of Form 4 filing. |
| 10/01/2030 | Expiration date of some employee stock options. |
| 08/01/2026 | Expiration date of some employee stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.